1. Home
  2. ARVN vs DRUG Comparison

ARVN vs DRUG Comparison

Compare ARVN & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$10.92

Market Cap

781.0M

Sector

Health Care

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$87.08

Market Cap

707.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARVN
DRUG
Founded
2015
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
781.0M
707.1M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
ARVN
DRUG
Price
$10.92
$87.08
Analyst Decision
Buy
Strong Buy
Analyst Count
19
6
Target Price
$15.05
$129.25
AVG Volume (30 Days)
781.8K
144.0K
Earning Date
05-04-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
58.84
N/A
EPS
N/A
N/A
Revenue
$262,600,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.90
$23.18
52 Week High
$14.22
$123.75

Technical Indicators

Market Signals
Indicator
ARVN
DRUG
Relative Strength Index (RSI) 44.75 63.01
Support Level $9.02 $69.83
Resistance Level $12.43 $91.00
Average True Range (ATR) 0.63 5.25
MACD 0.07 1.89
Stochastic Oscillator 44.71 87.13

Price Performance

Historical Comparison
ARVN
DRUG

About ARVN Arvinas Inc.

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: